Destiny Pharma: Chair’s Investor Update

Destiny Pharma: Publication of new data on NTCD-M3 confirms potential as an effective treatment for prevention of C. difficile infections

Marinomed to pause issuing of tranches of Convertible Notes Funding Program to Nice & Green

iOmx Therapeutics Announces the Appointment of Three New Supervisory Board Members

Spexis announces business update call to be held on July 28th

CEVEC’s license partner RZNOMICS Inc. receives approval to initiate clinical development of CAP® Ad Technology-produced gene therapy vector in liver cancer patients

Adrenomed appoints David Germonpré as Chief Financial Officer

VisionHealth and Boehringer Ingelheim: Digital therapy support for asthma and COPD

Destiny Pharma receives award from the Cystic Fibrosis Foundation

Heidelberg Pharma Reports on First Half-Year 2022